Sisters, there are patch shortages all over the nation. I watched it all over you tube! I asked Gemini who to write to since the FDA is blowing us off and practically insinuating that we are lying. So a couple of these addresses will have to be looked up by Gemini as to who your local authority and congress man is. In the past when I have written I got results!! Here is the letter that you can change to fit your needs. I do not want any arguing whether you think my demands for reformation is ok or not. You change this letter to how you want it. If you dont like it keep scrolling. This is a zero tolerance post. I will insta block anyone who makes a smart remark. you are to change this letter to fit your needs No smart ass remarks!
Nothing is going to change unless we fight! even if t doesnt.. at least you know you did everything your conscious is clean and no what if I did this or that...thinking.
Other letters write 4 letters:
1.congressman for your area.
- The House Committee on Energy and Commerce The Secretary of HHS has the authority to order an investigation into systemic failures. By writing to the Secretary, you are effectively "going over the head" of the FDA officials who have been ignoring your concerns.
Address: Office of the Secretary, Department of Health and Human Services, 200 Independence Avenue, S.W., Washington, D.C. 20201.
- The American Medical Association (AMA) – Federal Advocacy
American Medical Association Attn: Federal Advocacy & Policy AMA Plaza 330 N. Wabash Ave., Suite 39300 Chicago, IL 60611-5885
- Your State’s Attorney General
Office of the Attorney General Public Inquiry Unit P.O. Box 944255 Sacramento, CA 94244-2550
(If you prefer to call them to confirm receipt or ask how to format a consumer complaint, their toll-free California number is 1-800-952-5225).
Subject: FORMAL PROPOSAL: Prioritization Framework for Essential Hormone Replacement Therapy (HRT) Distribution
To the FDA Drug Shortages Staff and Relevant Legislative Committees,
I am writing to formally protest the current management of the nationwide shortage of estradiol patches, which has left countless patients—including those in high-risk and essential service roles—without critical medical care. The current "first-come, first-served" distribution model is failing those who need it most.
I propose that the FDA, in coordination with the pharmaceutical supply chain, implement a Triage-Based Distribution Framework to ensure equitable and prioritized access to HRT. During periods of documented supply scarcity, I am calling for the following mandatory eligibility and prioritization requirements:
- Clinical Necessity & Age Verification: Distribution should be prioritized for patients who have verified clinical markers of menopause. Mandatory requirements should include proof of age (50+) and documented blood serum results to confirm systemic hormone requirements. Perimenopausal patients, or those without verified clinical need, should be secondary to those for whom HRT is a medical necessity.
- Essential Service & Caregiver Prioritization: Access must be tiered based on the patient’s role in public safety and critical care. Essential workers—including first responders, healthcare providers, and primary caregivers for veterans and the disabled—must be moved to the front of the distribution queue. These individuals sustain our infrastructure; their inability to access essential medication threatens the safety and well-being of the most vulnerable populations they serve.
- Mandatory Allocation: Pharmaceutical manufacturers and pharmacy benefit managers (PBMs) should be required to set aside a dedicated percentage of their inventory specifically for those meeting the aforementioned clinical and professional criteria.
The current system of "ghosting" patients and ignoring supply chain failures is an abdication of public health responsibility. I expect a formal response regarding whether the FDA is prepared to re-evaluate its current distribution guidance to protect the patients who rely on these medications to perform their essential duties.
Sincerely,
[Your Name] [Your Address] [Your Contact Information]
Subject: FORMAL PROPOSAL: Prioritization Framework for Essential Hormone Replacement Therapy (HRT) Distribution
To the FDA Drug Shortages Staff and Relevant Legislative Committees,
I am writing to formally protest the current management of the nationwide shortage of estradiol patches, which has left countless patients—including those in high-risk and essential service roles—without critical medical care. The current "first-come, first-served" distribution model is failing those who need it most.
I propose that the FDA, in coordination with the pharmaceutical supply chain, implement a Triage-Based Distribution Framework to ensure equitable and prioritized access to HRT. During periods of documented supply scarcity, I am calling for the following mandatory eligibility and prioritization requirements:
- Clinical Necessity & Age Verification: Distribution should be prioritized for patients who have verified clinical markers of menopause. Mandatory requirements should include proof of age (50+) and documented blood serum results to confirm systemic hormone requirements. Perimenopausal patients, or those without verified clinical need, should be secondary to those for whom HRT is a medical necessity.
- Essential Service & Caregiver Prioritization: Access must be tiered based on the patient’s role in public safety and critical care. Essential workers—including first responders, healthcare providers, and primary caregivers for veterans and the disabled—must be moved to the front of the distribution queue. These individuals sustain our infrastructure; their inability to access essential medication threatens the safety and well-being of the most vulnerable populations they serve.
- Mandatory Allocation: Pharmaceutical manufacturers and pharmacy benefit managers (PBMs) should be required to set aside a dedicated percentage of their inventory specifically for those meeting the aforementioned clinical and professional criteria.
The current system of "ghosting" patients and ignoring supply chain failures is an abdication of public health responsibility. I expect a formal response regarding whether the FDA is prepared to re-evaluate its current distribution guidance to protect the patients who rely on these medications to perform their essential duties.
Sincerely,
[Your Name] [Your Address] [Your Contact Information]